Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#41 / 49 Total
RAND - Rand Capital Corp. - Stock Price Chart
TickerRAND [NASD]
CompanyRand Capital Corp.
CountryUSA
IndustryAsset Management
Market Cap38.26MEPS (ttm)2.53
P/E5.84EPS this Y840.10%
Forward P/E-EPS next Y-
PEG-EPS past 5Y47.80%
P/S5.24EPS next 5Y-
P/B0.63EPS Q/Q240.10%
Dividend6.68%Sales Q/Q11.80%
Insider Own76.03%Inst Own3.40%
Insider Trans0.15%Inst Trans1.15%
Short Float0.32%EarningsMay 13/b
Analyst Recom-Target Price-
Avg Volume1.34K52W Range12.17 - 14.51
Rand Capital Corporation is a business development company specializing in subordinated debt with warrants or preferred equity and venture capital investments. Within private equity, the firm specializing in capital growth and lower middle market investments. Within venture capital, it specializing in early to late-stage private businesses. It does not prefer to invest in real estate sector. It prefers to invest in software, professional services, manufacturing, consumer, healthcare, automotive and public d stocks. It prefers to invest in East or Midwest U.S. operations sectors. It typically invests between $0.75 million and $5 million with initial target size of $1.5 million. It seeks to invest in companies having more than $2 million in revenue or having excess of $1.5 million and up to $5 million in EBITDA. It prefers to be a minority stake and seeks to take a Board seat in its portfolio companies. It typically holds its investments for a period up to five years.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Godley Benjamin EDirectorMar 12 '24Buy13.951,96527,41225,000Mar 13 05:00 PM
Godley Benjamin EDirectorMar 07 '24Buy13.991832,56023,035Mar 08 05:00 PM
Godley Benjamin EDirectorMar 06 '24Buy13.9585211,88522,852Mar 08 05:00 PM
Godley Benjamin EDirectorAug 17 '23Buy13.151001,31522,000Aug 18 04:30 PM
Godley Benjamin EDirectorAug 16 '23Buy12.981,90024,66221,900Aug 18 04:30 PM
TCRX - Tscan Therapeutics Inc - Stock Price Chart
TickerTCRX [NASD]
CompanyTscan Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap369.26MEPS (ttm)-1.89
P/E-EPS this Y13.97%
Forward P/E-EPS next Y-13.50%
PEG-EPS past 5Y-25.53%
P/S17.54EPS next 5Y-
P/B2.54EPS Q/Q73.41%
Dividend-Sales Q/Q132.99%
Insider Own16.42%Inst Own59.67%
Insider Trans0.45%Inst Trans-0.36%
Short Float1.03%EarningsMay 13/b
Analyst Recom1.17Target Price12.00
Avg Volume210.48K52W Range1.93 - 9.09
May-13-24Initiated Needham Buy $11
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBERICH TIMOTHY JDirectorDec 19 '23Buy4.973171,57567,027Dec 21 05:00 PM
BARBERICH TIMOTHY JDirectorDec 18 '23Buy4.8928,830140,88166,710Dec 21 05:00 PM
Klencke BarbaraDirectorDec 14 '23Buy5.085,00025,40030,000Dec 18 06:01 PM
BARBERICH TIMOTHY JDirectorJun 02 '23Buy2.6337,88099,56437,880Jun 06 07:53 PM
Lynx1 Capital Management LP10% OwnerMay 31 '23Sale2.5225,40063,9525,224,600Jun 02 05:35 PM
TERN - Terns Pharmaceuticals Inc - Stock Price Chart
TickerTERN [NASD, RUT]
CompanyTerns Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap380.91MEPS (ttm)-1.27
P/E-EPS this Y-7.77%
Forward P/E-EPS next Y-1.12%
PEG-EPS past 5Y-12.40%
P/S-EPS next 5Y-
P/B1.49EPS Q/Q-0.45%
Dividend-Sales Q/Q-
Insider Own36.39%Inst Own77.42%
Insider Trans-1.76%Inst Trans32.54%
Short Float10.91%EarningsMay 13/b
Analyst Recom1.50Target Price14.21
Avg Volume946.52K52W Range3.26 - 13.23
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vivo Opportunity, LLC10% OwnerApr 03 '24Sale6.20138,066856,009268,573Apr 03 08:47 PM
Vivo Opportunity, LLC10% OwnerApr 02 '24Sale6.65101,480674,842272,722Apr 03 08:47 PM
Vivo Opportunity, LLC10% OwnerApr 01 '24Sale6.99181,1171,266,008275,772Apr 03 08:47 PM
TME - Tencent Music Entertainment Group ADR - Stock Price Chart
TickerTME [NYSE]
CompanyTencent Music Entertainment Group ADR
CountryChina
IndustryInternet Content & Information
Market Cap10.36BEPS (ttm)0.44
P/E33.47EPS this Y31.08%
Forward P/E21.79EPS next Y20.49%
PEG2.25EPS past 5Y19.83%
P/S2.64EPS next 5Y14.89%
P/B1.31EPS Q/Q16.16%
Dividend-Sales Q/Q-8.61%
Insider Own1.02%Inst Own62.68%
Insider Trans0.00%Inst Trans-1.64%
Short Float3.73%EarningsMay 13/b
Analyst Recom1.41Target Price13.36
Avg Volume7.85M52W Range5.70 - 13.66
Tencent Music Entertainment Group engages in the business of operating online music entertainment platforms to provide music streaming, online karaoke, and live streaming services. Its product brands include QQ Music, Kugou Music, Kuwo Music, and WeSing. The company was founded on June 6, 2012 and is headquartered in Shenzhen, China.
TRML - Tourmaline Bio Inc - Stock Price Chart
TickerTRML [NASD]
CompanyTourmaline Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap370.39MEPS (ttm)-6.50
P/E-EPS this Y68.79%
Forward P/E-EPS next Y-8.15%
PEG-EPS past 5Y-19.23%
P/S-EPS next 5Y-
P/B1.43EPS Q/Q89.73%
Dividend-Sales Q/Q-
Insider Own39.73%Inst Own42.68%
Insider Trans1.04%Inst Trans-7.46%
Short Float20.11%EarningsMay 13/b
Analyst Recom1.00Target Price58.33
Avg Volume431.81K52W Range9.18 - 48.31
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCDADE MARKDirectorJan 29 '24Buy32.50100,0003,250,000448,431Jan 31 04:26 PM
Kulkarni Sandeep ChidambarCEONov 17 '23Buy16.994,00067,960729,735Nov 20 06:15 PM
Thiara ParvinderDirectorNov 17 '23Buy17.311,00017,31083,782Nov 20 06:14 PM
Castelein CaleyDirectorOct 27 '23Buy14.5515,800229,890516,519Oct 27 05:43 PM
Kulkarni Sandeep ChidambarCEOOct 26 '23Buy12.255,00061,250725,735Oct 26 05:34 PM
URGN - UroGen Pharma Ltd - Stock Price Chart
TickerURGN [NASD, RUT]
CompanyUroGen Pharma Ltd
CountryUSA
IndustryBiotechnology
Market Cap472.22MEPS (ttm)-3.72
P/E-EPS this Y-1.97%
Forward P/E-EPS next Y27.12%
PEG-EPS past 5Y5.89%
P/S5.71EPS next 5Y-
P/B-EPS Q/Q41.19%
Dividend-Sales Q/Q30.06%
Insider Own15.70%Inst Own71.62%
Insider Trans-0.37%Inst Trans-0.53%
Short Float14.55%EarningsMay 13/b
Analyst Recom1.40Target Price38.50
Avg Volume340.43K52W Range8.69 - 24.13
May-13-24 12:53PM URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:32AM UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations (GuruFocus.com)
08:00AM UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights (Business Wire)
May-07-24 08:00AM UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
May-05-24 12:20PM New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy (Business Wire)
May-04-24 03:20PM UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 (Business Wire)
11:50AM New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial (Business Wire)
May-03-24 08:00AM UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 (Business Wire)
Apr-17-24 12:02PM UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers (Business Wire)
Apr-15-24 08:00AM UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schoenberg MarkChief Medical OfficerMar 18 '24Sale14.0512,000168,600139,437Mar 20 04:38 PM
Smith Jason DrewGeneral CounselJan 31 '24Sale15.744,99378,59018,824Feb 02 07:12 PM
Schoenberg MarkChief Medical OfficerJan 31 '24Sale15.743,78959,639149,423Feb 02 07:07 PM
Smith Jason DrewGeneral CounselAug 31 '23Sale18.013,80068,43818,407Sep 05 04:28 PM
VRCA - Verrica Pharmaceuticals Inc - Stock Price Chart
TickerVRCA [NASD, RUT]
CompanyVerrica Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap405.54MEPS (ttm)-1.46
P/E-EPS this Y-4.29%
Forward P/E-EPS next Y47.69%
PEG-EPS past 5Y-0.97%
P/S79.21EPS next 5Y-
P/B20.52EPS Q/Q-268.07%
Dividend-Sales Q/Q2823.53%
Insider Own39.25%Inst Own42.02%
Insider Trans13.06%Inst Trans-9.35%
Short Float14.06%EarningsMay 13/b
Analyst Recom1.00Target Price15.00
Avg Volume162.02K52W Range2.86 - 8.17
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerDec 29 '23Buy7.24115,774838,2047,099,182Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 28 '23Buy7.08126,116892,9016,983,408Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 27 '23Buy7.2079,726574,0276,857,292Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 26 '23Buy6.4954,652354,6916,777,566Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 22 '23Buy6.67250,0001,667,5006,722,914Dec 26 07:21 PM
VTRU - Vitru Ltd - Stock Price Chart
TickerVTRU [NASD]
CompanyVitru Ltd
CountryBrazil
IndustryEducation & Training Services
Market Cap374.53MEPS (ttm)0.59
P/E18.96EPS this Y101.77%
Forward P/E3.63EPS next Y47.14%
PEG1.33EPS past 5Y-
P/S0.95EPS next 5Y14.30%
P/B0.80EPS Q/Q-388.52%
Dividend1.50%Sales Q/Q25.28%
Insider Own60.53%Inst Own32.75%
Insider Trans0.00%Inst Trans1.33%
Short Float0.18%EarningsMay 13/b
Analyst Recom1.00Target Price24.76
Avg Volume18.37K52W Range9.80 - 18.05
Vitru Ltd. operates as a pure-player in the post-secondary digital education market. The firm provides a complete pedagogical ecosystem focused on hybrid distance learning experience for undergraduates and continuing education students. It operates through the following segments: Digital education undergraduate courses, Continuing education courses and On-campus undergraduate courses. The Digital education undergraduate courses segment offers educational content and support via internet and mobile devices and its portfolio of courses is composed mainly of pedagogy, business administration, accounting, physical education, vocational education, engineering and health-related courses. The Continuing education courses segment offers continuing education courses predominantly in pedagogy, finance and business and it offers courses in different versions like in a hybrid model, 100% online and on-campus. The On-campus undergraduate courses segment offers traditional on-campus undergraduate courses, including those that are currently not allowed to be offered through digital education, such as law and health-related courses, and others such as business administration, accounting, physical education, and engineering . The company was founded on March 5, 2020 and is headquartered in Florianopolis, Brazil.
XGN - Exagen Inc - Stock Price Chart
TickerXGN [NASD]
CompanyExagen Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap28.47MEPS (ttm)-1.34
P/E-EPS this Y4.89%
Forward P/E-EPS next Y25.92%
PEG-EPS past 5Y2.69%
P/S0.54EPS next 5Y-
P/B1.23EPS Q/Q62.57%
Dividend-Sales Q/Q7.23%
Insider Own53.72%Inst Own37.64%
Insider Trans-0.21%Inst Trans-0.83%
Short Float0.05%EarningsMay 13/b
Analyst Recom1.33Target Price5.50
Avg Volume33.58K52W Range1.30 - 3.92
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Adawi KamalCFO and Corporate SecretaryMar 04 '24Sale1.9112,78424,407243,749Mar 06 04:05 PM
Adawi KamalCFO and Corporate SecretaryFeb 06 '24Sale1.956,73813,133181,533Feb 08 04:05 PM
ABALLI JOHNPresident and CEOOct 17 '23Sale1.7533,81959,018415,984Oct 18 04:05 PM
TULLIS JAMES L L10% OwnerJun 15 '23Buy3.111675191,515,839Jun 20 05:04 PM
12345